Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)


Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., DANE F., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.139, ss.829-835, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 139 Konu: 5
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1007/s00432-013-1390-8
  • Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.829-835

Özet

The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.